Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
Revenue of Taysha Gene Therapies, Inc. (TSHA)
Revenue in 2023 (TTM): $15.45 M
According to Taysha Gene Therapies, Inc.'s latest financial reports the company's current revenue (TTM) is $15.45 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Taysha Gene Therapies, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $15.45 M | $14.08 M | $-70,003,000 | $-111,566,000 | $-111,566,000 |
| 2022 | $2.5 M | $15 K | $-125,796,000 | $-166,014,000 | $-169,581,000 |
| 2021 | $ | $-492,000 | $-173,095,000 | $-174,523,000 | $-175,459,000 |
| 2020 | $ | $-9,000 | $-59,983,000 | $-60,011,000 | $-43,000,000 |
| 2019 | $ | $ | $-1,115,000 | $-1,115,000 | $-1,115,000 |